Compare DTF & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DTF | ACET |
|---|---|---|
| Founded | 1991 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 71.3M |
| IPO Year | N/A | N/A |
| Metric | DTF | ACET |
|---|---|---|
| Price | $11.34 | $0.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 21.1K | ★ 2.9M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.29 | $0.45 |
| 52 Week High | $11.19 | $1.11 |
| Indicator | DTF | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 43.00 |
| Support Level | $11.33 | $0.47 |
| Resistance Level | $11.40 | $0.52 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 33.36 | 45.30 |
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.